Geopolitical Tensions Escalate as Iran Refuses Concessions Amid Strait Dispute Oil Markets on Edge Tulsi Gabbard Resigns as National Intelligence Director Citing Family Health Concerns Prediction Market Platforms Face Legal Crackdown from 16 States YearEnd Portfolio Adjustments Key Moves for Stock Market Investors Timex Group India Reports Rs 800 Crore Revenue for FY26 Profit Surges 151 Premier Energies Promoters Divest Rs 2289 Crore Stake to Institutional Investors Quant Nomura Among Buyers HDB Q1 2026 Earnings EPS Beats Estimates Amidst Market Skepticism RiverNorth Capital and Income Fund RSF Q4 2022 Earnings Significant EPS Beat Driven by Strong Portfolio Income MC Q1 2026 Earnings EPS Misses Estimates Amid Uncertain Deal Environment KORE Q1 2026 Earnings Massive EPS Miss Revenue Data Unavailable DSGR Q1 2026 Earnings EPS Beats Estimates Despite Modest Stock Decline Global Partners GLP Q1 2026 Earnings Massive EPS Surprise of 455 as Partnership Delivers Strong Results National Bankshares NKSH Edges Lower Amid Consolidation Near Support JDcom Stock Slips Amid ProfitTaking and Sector Headwinds Key Support Tested Tenaris TS Holds Steady Near Key Levels as Energy Sector Consolidates HASI Holds Steady Near 4061 as Support and Resistance Levels Come into Focus Teledyne Technologies TDY Recovers to 62045 as Defense and Industrial Demand Lifts Shares Wall Street Sentiment Shifts Positive for CoreWeave on AI Demand Outlook PED Q1 2026 Earnings Strong EPS Beat Offsets Investor Caution Amid Revenue Gap Elite Express Holding ETS Rises 343 Testing Key Resistance at 060 Trimble Inc TRMB Q1 2026 Earnings Strong Earnings Beat Despite Flat Stock Reaction Foreign Investment in Caribbean Coastlines Sparks Access Concerns in Barbuda Grenada and Jamaica NWFL Q1 2026 Earnings Strong Earnings Beat Driven by Solid Operational Performance Financial Services Roundup Market Talks Highlight Experian SoFi Technologies and Sector Trends CareDx Q1 2026 Earnings Robust Profit Beat Drives Optimism BLTE Q4 2025 Earnings WiderthanExpected Loss as PreRevenue Biotech Remains Focused on Clinical Development NCTY Q1 2012 Earnings NarrowerthanExpected Loss as ADR Edges Higher